The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Aim
Hepatitis C virus (HCV) infection has been reported to cause liver steatosis. Thus, eradicating HCV with direct‐acting antivirals (DAAs) is expected to reduce liver steatosis. We aimed to clarify long‐term changes in the prevalence of fatty liver and hyper‐low‐density lipoprotein (LDL) cholesterolemia and their associations in patients who achieve successful HCV eradication using DAAs.
Methods...
AimTelaprevir‐based therapy for chronic hepatitis C patients is effective; however, the high prevalence of dermatological reactions is an outstanding issue. The mechanism and characteristics of such adverse reactions are unclear; moreover, predictive factors remain unknown. Granulysin was recently reported to be upregulated in the blisters of patients with Stevens–Johnson syndrome (SJS). Therefore,...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.